Patents by Inventor Eric M. Chadwick

Eric M. Chadwick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
    Publication number: 20220002419
    Abstract: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
    Type: Application
    Filed: September 23, 2021
    Publication date: January 6, 2022
    Inventors: Zeren GAO, Steven D. LEVIN, Janine M. BILSBOROUGH, James W. West, Cameron S. BRANDT, Eric M. Chadwick
  • COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
    Publication number: 20190375843
    Abstract: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1?s ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
    Type: Application
    Filed: August 14, 2019
    Publication date: December 12, 2019
    Inventors: Zeren GAO, Steven D. LEVIN, Janine M. BILSBOROUGH, James W. WEST, Cameron S. BRANDT, Eric M. Chadwick
  • COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
    Publication number: 20180251556
    Abstract: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
    Type: Application
    Filed: May 7, 2018
    Publication date: September 6, 2018
    Inventors: Zeren GAO, Steven D. Levin, Janine M. Bilsborough, James W. West, Cameron S. Brandt, Eric M. Chadwick
  • Method of treating CD155 expressing cancers
    Patent number: 9994637
    Abstract: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: June 12, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zeren Gao, Steven D. Levin, Janine M. Bilsborough, James W. West, Cameron S. Brandt, Eric M. Chadwick
  • COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
    Publication number: 20170267763
    Abstract: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
    Type: Application
    Filed: June 1, 2017
    Publication date: September 21, 2017
    Inventors: Zeren GAO, Steven D. LEVIN, Janine M. BILSBOROUGH, James W. WEST, Cameron S. BRANDT, Eric M. Chadwick
  • Screening method for inhibitors of binding of zBR7R1 to CD155
    Patent number: 9695238
    Abstract: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: July 4, 2017
    Inventors: Zeren Gao, Steven D. Levin, Janine M. Bilsborough, James W. West, Cameron S. Brandt, Eric M. Chadwick
  • COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
    Publication number: 20160185863
    Abstract: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
    Type: Application
    Filed: March 14, 2016
    Publication date: June 30, 2016
    Inventors: Zeren GAO, Steven D. LEVIN, Janine M. BILSBOROUGH, James W. WEST, Cameron S. BRANDT, Eric M. Chadwick
  • COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
    Publication number: 20150152160
    Abstract: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
    Type: Application
    Filed: June 10, 2014
    Publication date: June 4, 2015
    Inventors: Zeren GAO, Steven D. Levin, Janine M. Bilsborough, James W. West, Cameron S. Brandt, Eric M. Chadwick
  • Methods of using IL-31 to treat chronic obstructive pulmonary disease (COPD)
    Patent number: 8298524
    Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: October 30, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri
  • COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
    Publication number: 20120219540
    Abstract: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
    Type: Application
    Filed: March 12, 2012
    Publication date: August 30, 2012
    Inventors: Zeren Gao, Steven D. Levin, Janine Bilsborough, James W. West, Cameron S. Brandt, Eric M. Chadwick
  • METHODS OF USING IL-31 TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    Publication number: 20120083456
    Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
    Type: Application
    Filed: August 23, 2011
    Publication date: April 5, 2012
    Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri
  • Methods of determining dose of IL-31 agonist to treat pulmonary inflammation
    Patent number: 8029775
    Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: October 4, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri
  • METHODS OF DETERMINING DOSE OF IL-31 AGONIST TO TREAT PULMONARY INFLAMMATION
    Publication number: 20110008820
    Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
    Type: Application
    Filed: August 26, 2010
    Publication date: January 13, 2011
    Inventors: JANINE M. BILSBOROUGH, ERIC M. CHADWICK, SHERRI L. MUDRI
  • COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
    Publication number: 20100316646
    Abstract: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
    Type: Application
    Filed: July 1, 2010
    Publication date: December 16, 2010
    Inventors: ZEREN GAO, STEVEN D. LEVIN, JANINE BILSBOROUGH, JAMES W. WEST, CAMERON S. BRANDT, ERIC M. CHADWICK
  • Methods of using IL-31 to treat airway hyper-responsiveness and asthma
    Patent number: 7799323
    Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proimflammatory cytokines and include administration of the IL-31 agonsit during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
    Type: Grant
    Filed: January 10, 2008
    Date of Patent: September 21, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri
  • COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
    Publication number: 20090156495
    Abstract: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
    Type: Application
    Filed: November 13, 2008
    Publication date: June 18, 2009
    Inventors: Zeren Gao, Steven D. Levin, Janine Bilsborough, James W. West, Cameron S. Brandt, Frederick J. Ramsdell, Edward D. Howard, Eric M. Chadwick
  • METHODS OF USING IL-31 TO TREAT AIRWAY HYPER-RESPONSIVENESS AND ASTHMA
    Publication number: 20080260686
    Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proimflammatory cytokines and include administration of the IL-31 agonsit during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
    Type: Application
    Filed: January 10, 2008
    Publication date: October 23, 2008
    Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri, Yue Yao, Hongping Ren, Jane A. Gross